Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history-Reference-Cited by-同舟云学术

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

Published:2009-10-01 Issue:1 Volume:24 Page:6-12
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Jabbour E,Hochhaus A,Cortes J,La Rosée P,Kantarjian H M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2009193.pdf

Reference46 articles.

1. Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293.

2. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277–280.

3. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

4. Sessions J . Chronic myeloid leukemia in 2007. J Manag Care Pharm 2007; 13: 4–7.

5. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of miRNA- 96 and miRNA-150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients;Human Gene;2023-05

2. The role of miRNA -181C between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients;Human Gene;2022-12

3. Prévalence des Effets Indésirables des Inhibiteurs de Tyrosine Kinase Utilisés dans le Traitement de la Leucémie Myéloïde Chronique au CHU de Sidi Bel-Abbès;Annales Pharmaceutiques Françaises;2022-11

4. ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors;Laboratory Medicine;2020-08-21

5. Bibliography;Genome Chaos;2019